Article

Tumor Volume: An Adjunct Prognostic Factor in Cutaneous Melanoma

Author and Disclosure Information

 

References

Results

There were 108 eligible cases in the 4-year time period in which tumor volume assessment could be determined based on the pathology report in conjunction with Breslow depth, mitotic index, presence or absence of ulceration, and tumor infiltrating response. Breslow depth ranged from 0.20 to 10.00 mm, with a median depth of 1.37 mm. Surface area ranged from 12.00 to 1720.00 mm2 (median, 100.00 mm2). Tumor volume was calculated by multiplying Breslow depth by surface area and ranged from 2.76 to 11,180.00 mm3 (median, 113.05 mm3)(Table 1). Ulceration was present in 18.69% of the tumors, 20.37% exhibited a brisk inflammatory host reaction, and 53.27% had a mitotic index of 1/mm2 or more. Tumor metastasis was noted in 40.74% (44/108) of patients (Table 2), all of whom had a primary melanoma with a Breslow depth greater than 1 mm. Only one T1 melanoma had a tumor volume greater than 250 mm3. Metastasis in patients with T2 (1- to 2-mm thick) and T3 (2- to 4-mm thick) melanoma was associated with a tumor volume greater than 250 mm3 in 16 of 26 patients (61.54%), and all 18 patients with T4 melanomas (>4-mm thick) had tumor volume greater than 250 mm3.

Pages

Recommended Reading

VIDEO: How red hair and freckles might raise your skin cancer risk
MDedge Dermatology
Moles quadruple risk for melanoma
MDedge Dermatology
More people die from thin melanomas than thick melanomas
MDedge Dermatology
VIDEO: MEK/BRAF combo puts brakes on BRAF-mutated advanced melanoma progression
MDedge Dermatology
Spontaneously Regressing Primary Nodular Melanoma of the Glans Penis
MDedge Dermatology
VIDEO: A new system for staging squamous cell carcinoma
MDedge Dermatology
Investigational nivolumab beats chemo in pretreated advanced melanoma
MDedge Dermatology
COMBI-v affirms combination MEK, BRAF blockade in melanoma
MDedge Dermatology
Nine weeks of biochemotherapy effective for high-risk melanoma
MDedge Dermatology
Sargramostim addition improves survival in metastatic melanoma
MDedge Dermatology

Related Articles